Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD
December 20 2022 - 9:15AM
Cassava Sciences, Inc. (Nasdaq: SAVA) announced today that a valued
and long-time member of the Company, Nadav Friedmann, PhD, MD, has
died following a brief journey with cancer, only recently
discovered.
“We mourn profoundly the passing of a cherished
colleague and friend,” said Remi Barbier, President and CEO. “For
over 20 years, he generously gave his talents, expertise and
integrity in support of our success. On behalf of our employees and
our Board of Directors, I extend our deepest condolences to Dr.
Friedmann’s family, friends and all those whose lives he
touched.”
Dr. Friedmann was an esteemed member of our
Board of Directors since 1998 and an Officer of the Company since
2001. He was also a force of nature in drug development, with eight
drug approvals to his name and authorship on countless scientific
papers and patents. Prior to joining Cassava Sciences, he served as
President & CEO of Daiichi Pharmaceutical Corp and held senior
leadership positions with Johnson & Johnson in R&D,
including Head of Biotechnology Research.
James W. Kupiec, MD, who has been serving as
Chief Clinical Development Officer of Cassava Sciences, will now
serve as Chief Medical Officer for the Company, effective
immediately.
In addition, pursuant to a resolution duly
adopted December 19, 2022, by majority vote of the remaining Board
of Directors of Cassava Sciences, the number of directors which
constitutes the entire Board of Directors is now fixed at six
directors, the majority of whom still consists of independent
outside directors.
About Cassava Sciences,
Inc.Cassava Sciences is a clinical-stage biotechnology
company based in Austin, Texas. Our mission is to detect and treat
neurodegenerative diseases, such as Alzheimer’s disease. For more
information, please visit: https://www.CassavaSciences.com
For More Information Contact:
Eric Schoen, Chief Financial Officer(512) 501-2450, or
eschoen@CassavaSciences.com
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Apr 2023 to Apr 2024